Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,256

Document Document Title
WO/2018/060373A1
The present invention relates to drugs derived from elafibranor. It relates more specifically to a composition comprising at least one active ingredient, characterised in that at least one active ingredient comprises an elafibranor metfo...  
WO/2018/060962A2
The present invention relates to metformin amino acid compounds (SLNs), pharmaceutical compositions thereof, and methods of using them for the treatment of hyperglycemia, diabetes, and Type 2 diabetes. The compounds can be synthesized us...  
WO/2018/060959A1
The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases o...  
WO/2018/053643A1
Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of...  
WO/2018/035408A1
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Ch...  
WO/2018/029618A1
An antibacterial compound of formula I, wherein X is selected from fluoro or bromo, effective against Gram negative and Gram positive bacteria, and in particular against non-fermenting multiresistant bacteria affecting patients suffering...  
WO/2018/014111A1
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours po...  
WO/2017/205828A1
This invention relates to using a guanidinium-based ionic liquid as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the absorbent is...  
WO/2017/205807A1
This invention relates to using a eutectic mixture of two ionic liquids, as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the abso...  
WO/2017/197510A1
A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly ...  
WO/2017/195086A1
The present invention provides novel metformin salts, method of preparing, and pharmaceutical compositions containing the same. The metformin sesquihydrochloride and metformin dihydrochloride according to the present invention has improv...  
WO/2017/176246A1
Compositions and methods for cleansing the eyelid and treating an ocular condition are disclosed herein. A method for treating an ocular condition involves cleansing an eyelid with a first ophthalmic composition, wherein the first ophtha...  
WO/2017/164813A1
D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanid...  
WO/2017/158379A1
The present invention provides a crystalline salt of chlorhexidine chloride having a spherical morphology under Scanning Electron Microscopy (SEM) comprising a chloride anion and a cation selected from the group consisting of calcium, so...  
WO/2017/118582A1
The invention relates to an aqueous plating bath composition for electroless deposition of nickel or a nickel alloy, the composition comprising: (i) a source of nickel ions, wherein the aqueous plating bath composition further comprises ...  
WO/2017/119562A1
The present invention relates to an antithrombotic, antiplatelet and anticoagulant pharmaceutical composition containing, as an active ingredient, a compound isolated from Scolopendra subspinipes. More specifically, the compound of the p...  
WO/2017/114224A1
The present invention discloses a creatine mother liquor separation and purification processing system, wherein the system includes a mother liquor tank for containing the mother liquor following creatine synthesis, the mother liquor tan...  
WO/2017/114226A1
Disclosed in the present invention is a method for separating and purifying a creatine mother liquor: by means of a liquor delivery tube, pumping a mother liquor after creatine synthesis to be separated in an electrodialyzer, wherein the...  
WO/2017/106312A1
Embodiments described herein provide methods of treating various diseases or disorders using Sigma1 modulating compounds alone or in combination with other therapeutic agents.  
WO/2017/078467A1
The present invention relates to a composition for skin permeation to deliver a protein into skin, wherein the composition comprises an ionic conjugate in which a cationic compound and a protein are ionically bound. As the ionic conjugat...  
WO/2017/070482A3
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.  
WO/2017/070482A2
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.  
WO/2017/065495A3
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...  
WO/2017/065495A2
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...  
WO/2017/063155A1
The present invention provides compounds of formula I. The present invention also provides a preparation method for the compounds and a medicine composition comprising the compounds. The medicine composition can be used for treating a bo...  
WO/2017/051761A1
The prodrug or a salt thereof according to the present invention is represented by the formula: D-X-L. (In the formula, D represents a useful compound and becomes D-X-H. X represents NR1, O, S, or Se. R1 represents a hydrogen atom, a sub...  
WO/2017/049245A2
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2017/049245A3
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2017/043842A1
The present invention relates to a method for preparing D-arginine and, more particularly, to a method for preparing D-arginine by photosplitting DL-arginine using D-3-bromocamphor-8-sulfonic acid or a salt thereof as a photosplitting ag...  
WO/2017/042099A1
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof wherein ASC is -N(R8)ASC-1; ASC-1 is C 2-C 5alkylene-N(R9a)R9b or C(=O)-C 1-C 4alkylene-N(R9a)R9b, wherein in alkylen...  
WO/2017/042126A1
The invention relates to a method for producing biguanide salts of formula (III) and s-triazines of the formula (V). R1 and R2 respectively represent hydrogen, halogen and alkyl and R3 and R4 each represent hydrogen, alkyl, cycloalkyl an...  
WO/2017/035668A1
An applicator can have an ampoule body for holding a medial liquid; a tab extending away from the ampoule body and being twistable or deflectable with respect to a longitudinal axis of the ampoule body; and a frangible region in between ...  
WO/2017/027971A1
The present application is directed to transdermal formulations for the delivery of berberine compounds to a subject for the treatment of berberine-responsive diseases. In particular, the transdermal formulation comprises: (a) an aqueous...  
WO/2017/025560A1
The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N'-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the...  
WO/2017/027582A1
Compounds, pharmaceutical compositions, methods and kits are described for treating or preventing neurodegenerative diseases such as Alzheimer's disease.  
WO/2017/023833A1
The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ~95°F to ~98.5°F (~35°C to ~36.7°C) to mitigate and delay the early onset ...  
WO/2017/018361A1
The present invention is a compound represented by general formula (A), a base and/or radical generator obtained by containing said compound, and the like. (In the formula: four R1 groups each independently represents a hydrogen atom or ...  
WO/2017/011917A1
Methods for treating polycystic kidney disease (PKD) in a subject comprising administering a 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK) modulator or activator. Also kits comprising AMPK modulator or activators and i...  
WO/2017/013573A1
In accordance with the present invention, disclosed herein is a fertilizer core particle and fertilizer granule. The fertilizer core particle has one or more fertilizer additives, one or more binders comprising a wax, and one or more pH ...  
WO/2016/202125A1
Disclosed are an intermediate, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-forma midine]phenyl-2-propenamide (II), applicable in preparing AZD9291 (I) and a preparation method for the intermediate. Preparation steps comprise: ...  
WO/2016/203069A1
The present invention relates to the production of ε-caprolactam by treating cyclohexanone oxime with salts derived from guanidinium cation, and in particular with the tosylate of cyanoguanidine ([CNG][TsO]). The invention of the presen...  
WO/2016/201128A1
The present application provides, inter alia, chemical compounds useful as synthesis intermediates, said compounds comprising one or more guanidinium moieties and a hypervalent iodine atom. Methods for making these compounds are also pro...  
WO/2016/199756A1
The ketone-based gas adsorbent according to the present invention is characterized by containing a primary amine compound. The primary amine compound is preferably at least one selected from the group consisting of hydrazide compounds, a...  
WO/2016/193284A1
The present invention relates to compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to method...  
WO/2016/195077A1
This novel guanidine compound having excellent bactericidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R7-R9 independently represents a hydrogen ato...  
WO/2016/191458A3
Provided herein are methods for treating diseases, disorders and/or medical conditions with pharmaceutical compositions consisting of an association of active principles that affect mitochondrial redox state. Also provided herein are met...  
WO/2016/190227A1
Provided is a novel substance that is a physiologically active substance affecting gravity tropism. The gravity tropism regulator according to the present invention comprises, as an active ingredient, at least one kind of compound select...  
WO/2016/180840A1
The present invention relates to the use of a catalyst of the formula (I) for the crosslinking of a curable composition. The catalyst of the formula (I) contains at least one aliphatic guanidine group. It is substantially odourless and n...  
WO/2016/178130A1
The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid composition...  
WO/2016/176771A1
The present description relates to an anti-aging composition comprising at least one plant extract. The composition can comprise at least two different anti-aging agents, wherein one the anti-aging agent is a plant extract. The combinati...  

Matches 1 - 50 out of 3,256